On Wednesday, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted for expanded usage recommendation for Merck & Co Inc's (NYSE:MRK) and Pfizer Inc's (NYSE:PFE) pneumococcal conjugate vaccines.
The CDC panel has recommended lowering the pneumococcal vaccination age from 65 to 50 years old.
"ACIP's vote to expand adult pneumococcal vaccination to now include all adults aged 50 and older marks an important milestone in Pfizer's long-standing commitment to reducing the burden of this life-threatening disease," Pfizer's chief medical affairs officer for global vaccines and antivirals, said Luis Jodar.
The 20 serotypes contained in Pfizer's PREVNAR 20 are estimated to cause over 2,000 deaths and more than 65,000 cases of invasive pneumococcal disease (IPD), including bacteremia and meningitis and community-acquired pneumonia annually in adults aged 50 to 64.
Between 2018 and 2022, more than half of IPD cases in people aged 50 to 64 were caused by these 20 serotypes.
In the presentation, ACIP highlighted that among adults aged 50–64 with pneumococcal disease, a high proportion (88%) of adults
had ≥1 condition with a risk-based pneumococcal vaccine indication.
The CDC's pneumococcal vaccines workgroup emphasized in its presentation that an age-based recommendation would likely increase vaccine uptake more effectively than a risk-based approach.
The expert panel also highlighted economic impact, serotype coverage, and health equity advantages to support its recommendation.
In June this year, the FDA approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.
It's the first pneumococcal conjugate vaccine specifically designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection.
Price Action: At the last check on Thursday, MRK stock was down 0.73% at $105.60, and PFE stock was down 1.02% at $28.57.
星期三，美国疾病控制与预防中心（CDC）的免疫规划咨询委员会（ACIP）投票赞成扩大默沙东和辉瑞的肺炎链球菌结合疫苗的使用推荐。
CDC小组建议将肺炎球菌疫苗接种年龄从65岁降低到50岁。
默沙东全球疫苗和抗病毒首席医学事务官路易斯·霍达尔表示：“ACIP投票决定将成人肺炎球菌疫苗扩展至所有50岁及以上成年人，这标志着辉瑞长期致力于减少这种危及生命的疾病负担的重要里程碑。”
辉瑞的PREVNAR 20中含有的20种血清型据估计每年会导致50岁至64岁成年人中超过2,000例死亡和65,000多例侵袭性肺炎球菌疾病（IPD）病例，包括血症、脑膜炎和社区获得性肺炎。
2018年至2022年，50至64岁人群中一半以上的IPD病例是由这20种血清型引起的。
ACIP在演示中强调，50至64岁患肺炎球菌疾病的成年人中有高比例（88%）的成年人
具有控制风险肺炎球菌疫苗适应症的≥1控件的成年人。
CDC的肺炎球菌疫苗工作组在演示中强调，基于年龄的推荐可能比基于风险的方法更有效地提高疫苗接种率。
专家小组还强调了经济影响、血清型覆盖范围以及卫生公平的优势，以支持其建议。
今年6月，FDA批准了默沙东的Capvaxive（肺炎球菌21价结合疫苗），用于预防21种细菌引起的严重肺炎球菌疾病。
这是首个专门设计用于保护成年人免受一种称为肺炎球菌的细菌造成的严重疾病和肺部感染的肺炎球菌结合疫苗。
价格走势：在上周四最新数据显示，MRk股价下跌0.73%，报105.60美元，而PFE股价下跌1.02%，报28.57美元。
